VIVANI MEDICAL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.66 USD | -0.60% |
|
-0.60% | +62.75% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 89.61M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.26
x | P/E ratio 2025 * |
-2.91
x | Employees | 36 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.60% | ||
| 1 week | -0.60% | ||
| Current month | +1.84% | ||
| 1 month | +2.47% | ||
| 3 months | -60.66% | ||
| 6 months | +74.74% | ||
| Current year | +62.75% |
1 week
1.55
1.67
1 month
1.552.01
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | 71 | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.63 | -0.61% | 54,151 |
| 24-05-30 | 1.64 | -.--% | 37,339 |
| 24-05-29 | 1.64 | -1.20% | 63,098 |
| 24-05-28 | 1.66 | -0.60% | 579,538 |
| 24-05-24 | 1.67 | +2.45% | 128,256 |
End-of-day quote Nasdaq, May 27, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-06-02
- Bio International Convention
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.63
USD
Average target price
8
USD
Spread / Average Target
+390.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.75% | 89.61M | |
| +13.73% | 130B | |
| -8.17% | 10.99B | |
| -4.33% | 8.35B | |
| +41.80% | 5.67B | |
| -21.94% | 4.72B | |
| +7.81% | 3.42B | |
| -10.26% | 2.76B | |
| -10.29% | 2.11B | |
| -13.58% | 1.92B |
- Stock Market
- Equities
- VANI Stock
